Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pediatric AIDS: a perspective for the oncologist.

M E Horowitz1, P A Pizzo

  • 1Pediatric Branch, National Cancer Institute.

Oncology (Williston Park, N.Y.)
|December 1, 1990
PubMed
Summary

New therapies for pediatric AIDS show promise, with continuous azidothymidine infusion improving neurodevelopmental deficits and immune markers in children with HIV infection. Other drug trials also show encouraging early results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Work-family issues and perceptions of stress among pediatric faculty and house staff.

Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association·2002
Same author

From a physician in Lower Manhattan.

The New England journal of medicine·2002
Same author

The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.

Neuro-oncology·2001
Same author

Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.

The Journal of infectious diseases·2001
Same author

Will current training programs prepare pediatricians to meet the health care needs of children in the 21st century? An opinion.

The Journal of pediatrics·2001
Same author

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.

The Journal of infectious diseases·2001

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Immunology
  • Neurovirology

Background:

  • Pediatric HIV infection rates in the US approached cancer diagnosis rates by the mid-1990s.
  • Acquired Immunodeficiency Syndrome (AIDS) in children presented significant therapeutic challenges.
  • Advances in antiretroviral therapy offered potential hope for managing pediatric HIV/AIDS.

Purpose of the Study:

  • To evaluate the efficacy of continuous infusion azidothymidine (AZT) in pediatric patients with HIV/AIDS.
  • To assess treatment responses, including neurodevelopmental, clinical, and immunological markers.
  • To explore preliminary results from other novel therapeutic agents.

Main Methods:

  • A pediatric clinical trial at the National Cancer Institute (NCI) administered continuous infusion azidothymidine.
  • Therapeutic outcomes were assessed through objective and subjective measures.
  • CD4+ T-cell counts were monitored as a key immunological marker.

Main Results:

  • All patients with neurodevelopmental deficits showed objective and subjective responses to AZT therapy.
  • Significant improvements were observed in appetite, weight gain, and reduction of lymphadenopathy and hepatosplenomegaly.
  • Increases in CD4+ T-cell counts were comparable to those seen in adult patients.

Conclusions:

  • Continuous infusion azidothymidine demonstrates therapeutic efficacy in pediatric HIV/AIDS, particularly in addressing neurodevelopmental deficits.
  • The treatment regimen yielded positive clinical and immunological responses in children.
  • Emerging therapies including dideoxycytidine, dideoxyinosine, and recombinant CD4 show preliminary promise for pediatric HIV/AIDS management.

Related Experiment Videos